Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings or view top-rated stocks.

6 brokerages have issued 1 year price targets for Avadel Pharmaceuticals' shares. Their AVDL share price forecasts range from $5.00 to $13.00. On average, they expect the company's stock price to reach $10.29 in the next twelve months. This suggests a possible upside of 113.4% from the stock's current price.
View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts.

Avadel Pharmaceuticals' stock was trading at $8.08 at the start of the year. Since then, AVDL stock has decreased by 40.3% and is now trading at $4.82.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AVDL earnings forecast.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) posted its quarterly earnings data on Tuesday, August, 9th. The company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.60. During the same period in the previous year, the company earned ($0.33) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Wealth Effects LLC (4.38%), Woodline Partners LP (2.69%), Renaissance Technologies LLC (1.45%), Pura Vida Investments LLC (1.34%), Modera Wealth Management LLC (0.72%) and Knott David M Jr (0.38%). Insiders that own company stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, Sandra L Hatten and Thomas S Mchugh.
View institutional ownership trends.

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVDL stock can currently be purchased for approximately $4.82.

Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $288.19 million and generates $22.33 million in revenue each year. The company earns $-77,330,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 485-1200, via email at investors@avadel.com, or via fax at 353-1526-1077.